stockrow
Friday 6 November 2026
Export CING’s income statement to Excel — free account
Cingulate Inc.
CING Healthcare Biotechnology
- EPS
- +58.7%
- Free cash flow
- −24.3%
Quarter to June 2026, against a year earlier
4.26
0.02
+0.47%
Follow CING
Alert me
Cingulate Inc. (CING) P/E ratio
Cingulate Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CGTX Cognition Therapeutics, Inc. compare | n/m |
| CNXU Conexeu Sciences Inc. compare | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| CING Cingulate Inc. | n/m |
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | n/m |
| CSBR Champions Oncology, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)